Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpha Tau Medical Ltd. - Ordinary Shares (NQ: DRTS )

4.030 +0.030 (+0.75%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alpha Tau Medical Ltd. - Ordinary Shares

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
-First patient treated in the feasibility and safety study of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of new and recurrent squamous cell carcinoma of the... 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation emitters for the treatment of advanced inoperable pancreatic cancer. 
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau to Present at Upcoming November Investor Conferences
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.